Drug Trial Radar · NCT04820309
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Jun 2, 2021
Primary completion
May 24, 2024
Study completion May 24, 2024
Sponsor
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily \[BID\]) for up to 52 weeks. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and characterize the pharmacokinetics of xanomeline and trospium after administration of KarXT.
Conditions
- Schizophrenia
Interventions
Xanomeline and Trospium Chloride CapsulesDrug
Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From time of consent to end of study (approximately 400 days)
Locations
117 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 011-238
Little Rock, Arkansas
Woodland International Research Group
Little Rock, Arkansas
Local Institution - 011-201
Rogers, Arkansas
Woodland Research Northwest
Rogers, Arkansas
Local Institution - 011-240
Anaheim, California
Advanced Research Center, Inc.
Anaheim, California
Clinical Innovations, Inc
Bellflower, California
Local Institution - 011-222
Bellflower, California
Local Institution - 011-263
Bellflower, California
Local Institution - 011-257
Cerritos, California
ATP Clinical Research Inc
Costa Mesa, California
ATP Clinical Research, Inc.
Costa Mesa, California
Local Institution - 011-206
Culver City, California
ProScience Research Group
Culver City, California
Local Institution - 011-253
Garden Grove, California
Local Institution - 011-202
Glendale, California
Behavioral Clinical Research, Inc.
Glendale, California
Omega Clinical Trials
La Habra, California
Omega Clinical Trials
La Habra, California
Alliance for Wellness dba Alliance for Research
Long Beach, California
Alliance for Wellness
Long Beach, California
North County Clinical Research (NCCR)
Oceanside, California
Excell Research Inc
Oceanside, California
Local Institution - 011-229
Oceanside, California
Local Institution - 011-242
Orange, California
NRC Research Institute
Orange, California
CNRI-Los Angeles, LLC
Pico Rivera, California
Local Institution - 011-244
Pico Rivera, California
CITrials
Riverside, California
Local Institution - 011-233
Riverside, California
CITrials
Santa Ana, California
Local Institution - 011-251
Santa Rosa, California
Siyan Clinical Research
Santa Rosa, California
Local Institution - 011-246
Sherman Oaks, California
Schuster Medical Research Institute
Sherman Oaks, California
Collaborative Neuroscience Research
Torrance, California
Local Institution - 011-252
Torrance, California
Local Institution - 011-224
Hallandale, Florida
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida
Local Institution - 011-261
Hollywood, Florida
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.